Sort   by:  
 Page size 
Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers1,2. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluati...
ORGANISM(S): Mus musculus 
Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers1,2. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluati...
ORGANISM(S): Mus musculus 
Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluation ...
ORGANISM(S): Mus musculus 
Samples from the Greek island of Crete, MANOLIS cohort
UK10K_COHORT_TWINS REL-2011-12-01
UK10K_COHORT_IMPUTATION REL-2012-06-02: imputation reference panel (20140306); Merged UK10K+1000Genomes Phase 3 imputation reference panel added (20160420)
For information about this sample set, please contact the sample custodian Nic Timpson: N.J.Timpson@bristol.ac.uk
UK10K_COHORT_ALSPAC REL-2012-06-02: Low-coverage whole genome sequencing; variant calling, genotype calling and phasing
UK10K_COHORT_TWINSUK REL-2012-06-02: Phenotype data
Sort   by:  
 Page size